Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.50 |
| ▸ | GNE | Q9Y223 | 1/20 | 0.50 |
| ▸ | LANCL2 | Q9NS86 | 1/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.45 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
| ▸ | PARP1 | P09874 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | SCN7A | Q01118 | 4/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.42 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.42 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.42 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7245767 | 0.89 | GNE (0.62) | SIGMAR1GNELANCL2RXFP1HRH4 | |
| Hydrochloric Acid SCHEMBL7252859 | 0.87 | GNE (0.60) | SIGMAR1GNELANCL2RXFP1HRH4 | |
| Tert-Butyl Formate SCHEMBL27815221 | 0.86 | SCN9A (0.42) | SIGMAR1GNELANCL2HRH4SCN7A | |
| SCHEMBL5237 | 0.85 | GNE (0.68) | GNEUSP2MAPK1SMN1; SMN2L3MBTL1 | |
| SCHEMBL2532948 | 0.84 | GNE (0.66) | GNEUSP2MAPK1SMN1; SMN2L3MBTL1 | |
| SCHEMBL1579475 | 0.83 | GNE (0.55) | GNELANCL2USP2MAPK1SMN1; SMN2 | |
| SCHEMBL3086677 | 0.81 | HRH4 (0.50) | SIGMAR1GNELANCL2RXFP1HRH4 | |
| SCHEMBL1554586 | 0.81 | RAB9A (0.50) | GNEMAPK1SMN1; SMN2 | |
| SCHEMBL21802051 | 0.81 | SIGMAR1 (0.50) | SIGMAR1GNELANCL2RXFP1HRH4 | |
| SCHEMBL30911660 | 0.81 | RAB9A (0.50) | GNEMAPK1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9765029-B2 | Pyridine compounds as sodium channel blockers | PURDUE PHARMA L.P. (US) | 2017-09-19 | — | — | US | disclosed |
| US-9765029-B2 | Pyridine compounds as sodium channel blockers | PURDUE PHARMA L.P. (US) | 2017-09-19 | — | — | US | disclosed |
| US-20150344465-A1 | PYRIDINE COMPOUNDS AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. | 2015-12-03 | — | — | US | disclosed |
| US-20150344465-A1 | PYRIDINE COMPOUNDS AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. | 2015-12-03 | — | — | US | disclosed |
| US-9120752-B2 | Pyridine compounds as sodium channel blockers | PURDUE PHARMA, L.P. (US) | 2015-09-01 | — | — | US | disclosed |
| US-9120752-B2 | Pyridine compounds as sodium channel blockers | PURDUE PHARMA, L.P. (US) | 2015-09-01 | — | — | US | disclosed |
| WO-2012007836-A1 | PYRIDINE COMPOUNDS AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA .LP. (US) | 2012-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150344465-A1 | PYRIDINE COMPOUNDS AS SODIUM CHANNEL BLOCKERS | SCN1B, CACNA1A, SCN1A | SIGMAR1 252/4885GNE 3733/4885LANCL2 4573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.